Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 6/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.51 |
| ▸ | HRH1 | P35367 | 4/20 | 0.51 |
| ▸ | HTR2A | P28223 | 3/20 | 0.51 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | HRH2 | P25021 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.51 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3927212 | 0.82 | CHRM3 (0.57) | CHRM3CHRM2CHRM1HRH1HTR2A | |
| Hydrochloric Acid SCHEMBL5180488 | 0.81 | CHRM3 (0.56) | CHRM3CHRM2CHRM1HRH1HTR2A | |
| SCHEMBL8858816 | 0.81 | CHRM2 (0.55) | CHRM3CHRM2CHRM1HRH1HTR2A | |
| Diisopromine SCHEMBL25648 | 0.78 | HRH1 (0.63) | CHRM3CHRM2CHRM1HRH1HTR2A | |
| SCHEMBL13980083 | 0.77 | CHRM3 (0.67) | CHRM3CHRM2CHRM1HRH1HTR2A | |
| SCHEMBL2167561 | 0.77 | CHRM3 (0.67) | CHRM3CHRM2CHRM1HRH1HTR2A | |
| Diisopromine SCHEMBL11582569 | 0.76 | HRH1 (0.61) | CHRM3CHRM2CHRM1HRH1HTR2A | |
| SCHEMBL6939192 | 0.76 | CHRM3 (0.72) | CHRM3CHRM2CHRM1HRH1HTR2A | |
| SCHEMBL4664069 | 0.76 | CHRM3 (0.72) | CHRM3CHRM2CHRM1HRH1HTR2A | |
| SCHEMBL27530643 | 0.76 | HRH1 (0.56) | CHRM3CHRM2CHRM1HRH1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101124197-A | Substantially pure tolterodine tartrate and process for preparing thereof | TEVA PHARMA (IL) | 2008-02-13 | — | — | CN | disclosed |
| CN-101102995-A | Preparation method of tolterodine tartrate | TEVA PHARMA (IL) | 2008-01-09 | — | — | CN | disclosed |
| EP-1843999-A1 | PROCESS FOR PREPARING TOLTERODINE TARTRATE | Teva Pharmaceutical Industries Ltd (IL) | 2007-10-17 | — | — | EP | disclosed |
| EP-1836156-A1 | SUBSTANTIALLY PURE TOLTERODINE TARTRATE AND PROCESS FOR PREPARING THEREOF | Teva Gyogyszergyar Reszvenytarsasag (HU) | 2007-09-26 | — | — | EP | disclosed |
| US-20060194876-A1 | Substantially pure tolterodine tartrate and process for preparing thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-08-31 | — | — | US | disclosed |
| US-20060194987-A1 | Process for preparing tolterodine tartrate | TEVA PHARMACEUTICALS USA, INC. | 2006-08-31 | — | — | US | disclosed |
| WO-2006074478-A1 | SUBSTANTIALLY PURE TOLTERODINE TARTRATE AND PROCESS FOR PREPARING THEREOF | TEVA PHARMACEUTICALS USA, INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| WO-2006074479-A1 | PROCESS FOR PREPARING TOLTERODINE TARTRATE | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194876-A1 | Substantially pure tolterodine tartrate and process for preparing thereof | CYP17A1, TPP1, THOP1 | CHRM3 246/4885CHRM2 484/4885CHRM1 820/4885 |
| US-20060194987-A1 | Process for preparing tolterodine tartrate | TACR1, CYP3A43, TKT | CHRM3 178/4885CHRM2 716/4885CHRM1 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.